Feds Deciding When Healthcare Science Costs Too Much To Save Lives
Food and Drug Administration wants to de-list the cancer drug Avastin
By Warner Todd Huston —— Bio and Archives--October 22, 2010
American Politics, News | Comments | Back To Full Article
If anyone wants a current example of what is looming ahead for medical science at the hands of Obamacare, the Avastin controversy is a perfect one. The Food and Drug Administration (FDA) wants to de-list the cancer drug Avastin one reason being that it is a drug too expensive for government to fund. It is scary to think that the federal government can summarily dismiss cancer drugs merely because of expense, but that is what happens when government starts counting the beans. It becomes an issue of cost instead of effectiveness.
Read Full Article...
Welcome to CFP’s Comment Section!
The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.
Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.
Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.
We ask only that commenters keep it civil, keep it clean.
Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.
READ OUR Commenting Policy